Sigyn Therapeutics Inc (SIGY)
5.25
0.00 (0.00%)
USD |
OTCM |
Jun 24, 16:00
Sigyn Therapeutics Enterprise Value: 8.874M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 8.874M |
| June 24, 2024 | 8.874M |
| June 21, 2024 | 8.874M |
| June 20, 2024 | 8.874M |
| June 18, 2024 | 8.874M |
| June 17, 2024 | 8.874M |
| June 14, 2024 | 8.874M |
| June 13, 2024 | 8.874M |
| June 12, 2024 | 8.874M |
| June 11, 2024 | 8.874M |
| June 10, 2024 | 8.874M |
| June 07, 2024 | 8.874M |
| June 06, 2024 | 8.874M |
| June 05, 2024 | 8.874M |
| June 04, 2024 | 8.874M |
| June 03, 2024 | 8.874M |
| May 31, 2024 | 8.874M |
| May 30, 2024 | 8.874M |
| May 29, 2024 | 8.874M |
| May 28, 2024 | 8.874M |
| May 24, 2024 | 8.874M |
| May 23, 2024 | 8.874M |
| May 22, 2024 | 8.874M |
| May 21, 2024 | 8.874M |
| May 20, 2024 | 8.874M |
| Date | Value |
|---|---|
| May 17, 2024 | 8.874M |
| May 16, 2024 | 8.874M |
| May 15, 2024 | 8.874M |
| May 14, 2024 | 8.568M |
| May 13, 2024 | 8.568M |
| May 10, 2024 | 8.568M |
| May 09, 2024 | 8.568M |
| May 08, 2024 | 8.568M |
| May 07, 2024 | 8.568M |
| May 06, 2024 | 8.874M |
| May 03, 2024 | 8.874M |
| May 02, 2024 | 8.874M |
| May 01, 2024 | 9.180M |
| April 30, 2024 | 9.793M |
| April 29, 2024 | 10.21M |
| April 26, 2024 | 10.21M |
| April 25, 2024 | 9.487M |
| April 24, 2024 | 9.487M |
| April 23, 2024 | 9.487M |
| April 22, 2024 | 9.487M |
| April 19, 2024 | 9.487M |
| April 18, 2024 | 9.180M |
| April 17, 2024 | 9.915M |
| April 16, 2024 | 9.915M |
| April 15, 2024 | 9.915M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.964M
Minimum
Aug 14 2020
111.31M
Maximum
Feb 19 2021
16.57M
Average
9.243M
Median
Mar 15 2023
Enterprise Value Benchmarks
| CEL-SCI Corp | 61.31M |
| AIM ImmunoTech Inc | 11.80M |
| IGC Pharma Inc | 31.39M |
| NovaBay Pharmaceuticals Inc | 2.939M |
| Protalix BioTherapeutics Inc | 66.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.7581M |
| Total Expenses (Quarterly) | 0.63M |
| EPS Diluted (Quarterly) | -0.62 |
| Earnings Yield | -60.76% |
| Normalized Earnings Yield | -4515.18 |